文献速递乳腺癌

伊帕他塞替联合紫杉醇对比安慰剂联合紫杉醇一线治疗转移性三阴性乳腺癌(LOTUS):一项多中心、随机、双盲、安慰剂对照的2期试验

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2017-08-08

LOTUS研究纳入124例既往未接受系统治疗的转移性三阴性乳腺癌患者,随机接受紫杉醇联合伊帕他塞替或安慰剂治疗。意向治疗人群中,伊帕他塞替组中位无进展生存期为6.2个月,安慰剂组为4.9个月(分层HR 0.60,95%CI 0.37-0.98;p=0.037)。伊帕他塞替组最常见≥3级不良事件为腹泻(23%)。

要点

  • 意向治疗人群伊帕他塞替组中位PFS 6.2个月 vs 安慰剂组4.9个月,分层HR 0.60(95%CI 0.37-0.98;p=0.037)。
  • PTEN低表达患者中位PFS 6.2个月 vs 3.7个月,分层HR 0.59(95%CI 0.26-1.32;p=0.18),未达统计学显著。
  • 伊帕他塞替组≥3级腹泻14例(23%) vs 安慰剂组0例。

核心结论

  • 接受伊帕他塞替治疗的患者无进展生存期长于接受安慰剂的患者。
  • 据作者所知,这是首批支持AKT靶向治疗用于三阴性乳腺癌的结果。
  • 伊帕他塞替值得进一步研究用于三阴性乳腺癌的治疗。

研究设计与样本

  • 随机、安慰剂对照、双盲、2期试验,在韩国、美国、法国、西班牙、台湾、新加坡、意大利和比利时的44家医院开展。
  • 纳入18岁及以上、可测量、不可手术的局部晚期或转移性三阴性乳腺癌患者,既往未接受系统治疗。
  • 124例患者按1:1随机分配至紫杉醇联合伊帕他塞替组(n=62)或紫杉醇联合安慰剂组(n=62)。
  • 分层因素为既往(新)辅助治疗、无化疗间期和肿瘤PTEN状态。

主要发现

  • 意向治疗人群中位无进展生存期伊帕他塞替组6.2个月(95%CI 3.8-9.0) vs 安慰剂组4.9个月(95%CI 3.6-5.4),分层HR 0.60(95%CI 0.37-0.98;p=0.037)。
  • PTEN低表达肿瘤48例患者中位无进展生存期伊帕他塞替组6.2个月(95%CI 3.6-9.1) vs 安慰剂组3.7个月(95%CI 1.9-7.3),分层HR 0.59(95%CI 0.26-1.32;p=0.18)。
  • 最常见≥3级不良事件:腹泻伊帕他塞替组14例(23%,共61例) vs 安慰剂组0例(共62例);中性粒细胞计数降低5例(8%) vs 4例(6%);中性粒细胞减少6例(10%) vs 1例(2%)。
  • 伊帕他塞替组未报告结肠炎、4级腹泻或治疗相关死亡;安慰剂组发生1例治疗相关死亡。
  • 严重不良事件伊帕他塞替组17例(28%,共61例) vs 安慰剂组9例(15%,共62例)。

关键数值与推荐

  • 伊帕他塞替400 mg每日一次(第1-21天),联合紫杉醇80 mg/m2静脉给药(第1、8、15天),每28天为一周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文报告伊帕他塞替值得进一步研究用于三阴性乳腺癌的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium. Enrolled patients were randomly assigned (1:1) to receive intravenous paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity. Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumour PTEN status. The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochemistry) population. This ongoing trial is registered with ClinicalTrials.gov (NCT02162719). FINDINGS: Between Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62). Median follow-up was 10·4 months (IQR 6·5-14·1) in the ipatasertib group and 10·2 months (6·0-13·6) in the placebo group. Median progression-free survival in the intention-to-treat population was 6·2 months (95% CI 3·8-9·0) with ipatasertib versus 4·9 months (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumours, median progression-free survival was 6·2 months (95% CI 3·6-9·1) with ipatasertib versus 3·7 months (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18). The most common grade 3 or worse adverse events were diarrhoea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]). No colitis, grade 4 diarrhoea, or treatment-related deaths were reported with ipatasertib. One treatment-related death occurred in the placebo group. Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group. INTERPRETATION: Progression-free survival was longer in patients who received ipatasertib than in those who received placebo. To our knowledge, these are the first results supporting AKT-targeted therapy for triple-negative breast cancer. Ipatasertib warrants further investigation for the treatment of triple-negative breast cancer. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017. PMID: 28800861. doi:10.1016/S1470-2045(17)30450-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。